Daunorubicin Hydrochloride Injection USP 20 mg

Daunorubicin hydrochloride is the hydrochloride salt of an anthracycline cytotoxic antibiotic produced by a strain of Streptomyces coeruleorubidus. It is provided as a sterile reddish lyophilized powder in vials for intravenous administration only. Daunorubicin hydrochloride has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Daunorubicin hydrochloride forms complexes with DNA by intercalation between base pairs. It inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Single strand and double strand DNA breaks result.

There are many generic manufacturers in India who manufacture Daunorubicin Hydrochloride Injection USP 20 mg including United Biotech(P) Ltd etc.

3s corporation is Supplier,Exporter ,Wholesaler  for Daunorubicin Hydrochloride Injection USP 20 mg in India.

Daunorubicin Hydrochloride  in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. The reconstituted solution is stable for 24 hours at room temperature and 48 hours under refrigeration.

Starting Doses :
The recommended dosage in each individual may vary from 0.5 to 3 mg/ kg.

Acute non-lymphoytic leukemia
Patients <60 yrs. of age : 45mg/m²/day.

Patients >60 yrs. of age : 30mg/m²/day.

Acute Lymphocytic Leukemia (ALL)
Paediatric : 25mg/m2

Adult : 45mg/m2

Rarely, anaphylactoid reaction, fever, and chills can occur. Hyperuricemia may occur, especially in patients with leukemia, and serum uric acid levels should be monitored.

Bone Marrow

Daunorubicin Hydrochloride Injection is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of this drug. Therapy withDaunorubicin Hydrochloride Injection should not be started in patients with pre-existing drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk. Persistent, severe myelosuppression may result in superinfection or hemorrhage.